Breaking News

About the CMO Step-Up Challenge What is the #CMOStepUp Challenge all about, you may ask? It’s a step challenge where participants will compete to clock the most steps and emerge victorious with the Meta Quest VR Headset as their reward. All you need is a step counter, be it a handy app on your smartphone…

Greetings and salutations! It’s time for the March issue of the Medication Monitoring Matters newsletter, where we delve into cutting-edge advancements in medication adherence monitoring. In this edition, we’ll examine the potential downsides of Video Directly Observed Therapy (VDOT) as a monitoring solution and review adherence measurement trends for medicines approved by the European Medicines…

Drug trials are conducted to evaluate the safety and efficacy of new or investigational drugs. The primary goal of drug trials is to determine if a new drug is effective in treating a particular medical condition and if it is safe for use in the general population. In this context, medication adherence is crucial because it…

In clinical trial analysis, it’s assumed that participants are following the instructions for the investigational product. Unfortunately, the evidence suggests that this is far from reality. Recently, Kenneth Getz, Executive Director and Professor at the Tufts Center for the Study of Drug Development, shared in a Q&A session with AARDEX Group how digitalization is finally…

“Objective and granular” digital adherence measures could improve trial efficiency and allow for better-informed decisions on the efficacy and safety of new drug products. That’s according to the authors of a literature review that looked at more than 100 medicines approved by the European Medicines Agency (EMA) between 2010 and 2020. They found that while…

Greetings from the forefront of innovation in clinical trials. We’re thrilled to introduce you to the first edition of our medication adherence newsletter, Medication Monitoring Matters. Our focus? Empowering clinical trial sponsors like you to elevate the standard of care through improved adherence.  We’ll be sharing valuable insights, best practices, and the latest advancements in…

With the current push for increased diversity in research, the medical community has accepted the challenge to make trial populations more representative of those in clinical practice. Yet poor medication adherence, which clouds the view of how drugs work in the real world, continues to grow as a significant problem which ultimately jeopardizes drug development.  …

Seamless integration of adherence and research data protects participant safety and data quality, with no additional burden for clinical trial sites or participants Liege, Belgium- February 2, 2023: Adherence specialists AARDEX Group and remote research platform experts in the Clinpal team at Cambridge Cognition have teamed up to provide next-level adherence monitoring during hybrid and decentralized clinical trials (DCTs). Integrating AARDEX Group’s…

Poor medication adherence during clinical trials can skew results, leading to underestimations of product efficacy, inaccurate pharmacokinetic/pharmacodynamic calculations, and even put participant safety at risk.1 Research has shown that up to 50% of people who take part in drug development research do not take their medicines as prescribed.1 Despite this, there remains no systematic approach to…

The World Health Organization (WHO) has recently highlighted how poor adherence can lead to poorer outcomes for prisoners, contributing to health inequalities the world over. But it is worth noting that near-perfect adherence can be just as troublesome within the current drug development landscape.  With medication administration being almost compulsory behind bars, people can fall…